Univariable and multivariable analysis for major bleeding within 1 year of cancer-associated SpVT diagnosis
| Characteristic . | Major bleeding n (%) . | Unadjusted RR (95% CI) . | Adjusted∗ RR (95% CI) . |
|---|---|---|---|
| Age at thrombosis | |||
| ≤65 y | 39 (12.7) | Ref | Ref |
| >65 y | 23 (8.4) | 0.67 (0.41-1.08) | 0.67 (0.30-1.51) |
| Sex | |||
| Female | 11 (5.2) | Ref | Ref |
| Male | 51 (13.9) | 2.66 (1.42-4.99) | 2.42 (1.27-4.59) |
| Cirrhosis | |||
| Absent | 35 (10.8) | Ref | Ref |
| Present | 27 (10.5) | 0.97 (0.61-1.56) | 0.73 (0.41-1.31) |
| Abdominal surgery within past 3 mo | |||
| Absent | 58 (10.6) | Ref | Ref |
| Present | 4 (11.4) | 1.08 (0.41-2.79) | 1.03 (0.37-2.83) |
| Previous major bleed | |||
| Absent | 52 (10.1) | Ref | Ref |
| Present | 10 (14.9) | 1.48 (0.79-2.76) | 1.50 (0.79-2.84) |
| Baseline creatinine | |||
| ≤1.0 | 43 (9.5) | Ref | Ref |
| >1.0 | 19 (14.6) | 1.53 (0.93-2.54) | 1.44 (0.83-2.49) |
| Recent systemic chemotherapy | |||
| Absent | 51 (11.0) | Ref | Ref |
| Present | 11 (9.5) | 0.86 (0.47-1.61) | 1.13 (0.60-2.11) |
| Use of antiplatelet therapy at baseline | |||
| Absent | 45 (9.6) | Ref | Ref |
| Present | 17 (15.0) | 1.56 (0.93-2.63) | 1.46 (0.85-2.52) |
| Type of thrombus | |||
| Bland/mixed | 46 (10.5) | Ref | Ref |
| Tumor | 14 (12.2) | 1.16 (0.66-2.04) | 1.24 (0.71-2.18) |
| Thrombus occlusion | |||
| Partial | 20 (16.3) | Ref | Ref |
| Complete | 27 (10.2) | 0.63 (0.37-1.08) | 0.69 (0.40-1.17) |
| Anticoagulation within 2 wk | |||
| Absent | 31 (8.8) | Ref | Ref |
| Present | 31 (13.6) | 1.55 (0.97-2.48) | 1.74 (1.08-2.81) |
| Thrombocytopenia | |||
| None | 34 (11.0) | Ref | Ref |
| Platelets 75 × 103/μL - 99 × 103/μL | 8 (12.3) | 1.12 (0.55-2.31) | 0.86 (0.39-1.90) |
| Platelets 50 × 103/μL - 74 × 103/μL | 3 (4.2) | 0.38 (0.12-1.20) | 0.33 (0.10-1.03) |
| Platelets <50 × 103/μL | 10 (15.4) | 1.40 (0.73-2.69) | 1.21 (0.60-2.44) |
| Thrombocytopenia at baseline | |||
| None | 34 (11.0) | Ref | Ref |
| Platelets <100 × 103/μL | 21 (10.4) | 0.95 (0.57-1.59) | 0.76 (0.43-1.34) |
| Vessel involvement | |||
| Single | 49 (10.8) | Ref | Ref |
| Multiple | 13 (10.3) | 0.96 (0.54-1.71) | 0.89 (0.48-1.65) |
| Type of cancer | |||
| Hepatobiliary | 37 (11.5) | Ref | Ref |
| Pancreatic | 16 (12.7) | 1.10 (0.64-1.91) | 1.15 (0.66-2.02) |
| Luminal GI | 4 (8.2) | 0.71 (0.26-1.90) | 0.70 (0.27-1.82) |
| Other | 5 (5.9) | 0.51 (0.21-1.26) | 0.57 (0.23-1.46) |
| Characteristic . | Major bleeding n (%) . | Unadjusted RR (95% CI) . | Adjusted∗ RR (95% CI) . |
|---|---|---|---|
| Age at thrombosis | |||
| ≤65 y | 39 (12.7) | Ref | Ref |
| >65 y | 23 (8.4) | 0.67 (0.41-1.08) | 0.67 (0.30-1.51) |
| Sex | |||
| Female | 11 (5.2) | Ref | Ref |
| Male | 51 (13.9) | 2.66 (1.42-4.99) | 2.42 (1.27-4.59) |
| Cirrhosis | |||
| Absent | 35 (10.8) | Ref | Ref |
| Present | 27 (10.5) | 0.97 (0.61-1.56) | 0.73 (0.41-1.31) |
| Abdominal surgery within past 3 mo | |||
| Absent | 58 (10.6) | Ref | Ref |
| Present | 4 (11.4) | 1.08 (0.41-2.79) | 1.03 (0.37-2.83) |
| Previous major bleed | |||
| Absent | 52 (10.1) | Ref | Ref |
| Present | 10 (14.9) | 1.48 (0.79-2.76) | 1.50 (0.79-2.84) |
| Baseline creatinine | |||
| ≤1.0 | 43 (9.5) | Ref | Ref |
| >1.0 | 19 (14.6) | 1.53 (0.93-2.54) | 1.44 (0.83-2.49) |
| Recent systemic chemotherapy | |||
| Absent | 51 (11.0) | Ref | Ref |
| Present | 11 (9.5) | 0.86 (0.47-1.61) | 1.13 (0.60-2.11) |
| Use of antiplatelet therapy at baseline | |||
| Absent | 45 (9.6) | Ref | Ref |
| Present | 17 (15.0) | 1.56 (0.93-2.63) | 1.46 (0.85-2.52) |
| Type of thrombus | |||
| Bland/mixed | 46 (10.5) | Ref | Ref |
| Tumor | 14 (12.2) | 1.16 (0.66-2.04) | 1.24 (0.71-2.18) |
| Thrombus occlusion | |||
| Partial | 20 (16.3) | Ref | Ref |
| Complete | 27 (10.2) | 0.63 (0.37-1.08) | 0.69 (0.40-1.17) |
| Anticoagulation within 2 wk | |||
| Absent | 31 (8.8) | Ref | Ref |
| Present | 31 (13.6) | 1.55 (0.97-2.48) | 1.74 (1.08-2.81) |
| Thrombocytopenia | |||
| None | 34 (11.0) | Ref | Ref |
| Platelets 75 × 103/μL - 99 × 103/μL | 8 (12.3) | 1.12 (0.55-2.31) | 0.86 (0.39-1.90) |
| Platelets 50 × 103/μL - 74 × 103/μL | 3 (4.2) | 0.38 (0.12-1.20) | 0.33 (0.10-1.03) |
| Platelets <50 × 103/μL | 10 (15.4) | 1.40 (0.73-2.69) | 1.21 (0.60-2.44) |
| Thrombocytopenia at baseline | |||
| None | 34 (11.0) | Ref | Ref |
| Platelets <100 × 103/μL | 21 (10.4) | 0.95 (0.57-1.59) | 0.76 (0.43-1.34) |
| Vessel involvement | |||
| Single | 49 (10.8) | Ref | Ref |
| Multiple | 13 (10.3) | 0.96 (0.54-1.71) | 0.89 (0.48-1.65) |
| Type of cancer | |||
| Hepatobiliary | 37 (11.5) | Ref | Ref |
| Pancreatic | 16 (12.7) | 1.10 (0.64-1.91) | 1.15 (0.66-2.02) |
| Luminal GI | 4 (8.2) | 0.71 (0.26-1.90) | 0.70 (0.27-1.82) |
| Other | 5 (5.9) | 0.51 (0.21-1.26) | 0.57 (0.23-1.46) |
Adjusted for age at thrombosis (continuous), sex, previous major bleed, baseline creatinine (continuous), use of antiplatelets, use of therapeutic anticoagulants within 2 weeks of diagnosis, and type of cancer.